Scarica l'app Stockscreener
2.25
0.88%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$2.27
Aprire:
$2.26
Volume 24 ore:
334.87K
Relative Volume:
0.39
Capitalizzazione di mercato:
$239.44M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-6.6176
EPS:
-0.34
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
+11.39%
1M Prestazione:
+0.90%
6M Prestazione:
-51.72%
1 anno Prestazione:
-51.30%
Intervallo 1D:
$2.18
$2.27
Intervallo di 1 settimana:
$2.02
$2.37
Portata 52W:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.25 | 241.34M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-22 | Iniziato | Stephens | Overweight |
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
What drives MaxCyte Inc. stock priceHigh-yield investments - PrintWeekIndia
What makes MaxCyte Inc. stock attractive to long term investorsRapid growth trajectories - jammulinksnews.com
How MaxCyte Inc. stock performs during market volatilitySmart Growth Low Risk Picks - Newser
Is MaxCyte Inc. a good long term investmentHigh-return market picks - PrintWeekIndia
What analysts say about MaxCyte Inc. stockRapid portfolio appreciation - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - Autocar Professional
Published on: 2025-07-23 21:52:41 - Autocar Professional
Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - 富途牛牛
MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia
PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama
Business Wire - JIJI PRESS
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks
MaxCyte to delist shares from London AIM, maintains Nasdaq listing - Investing.com
Moving Gene Editing Advances Into the Clinic - the-scientist.com
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Soleymannezhad Ali | Chief Commercial Officer |
Mar 18 '25 |
Sale |
3.18 |
1,211 |
3,850 |
59,439 |
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):